Trial Profile
A Non-randomized Two Part Multi-center, Open-label, Single Dose Trial With an Escalation Part in Untreated Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients (Part A), Followed by a Parallel-group Part in Untreated and Pre-treated Patients With PAH and CTEPH (Part B) to Investigate the Safety, Tolerability and Pharmacodynamics of Inhaled BAY1237592
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs BAY 1237592 (Primary)
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms ATMOS
- Sponsors Bayer
- 07 Nov 2022 Status changed from active, no longer recruiting to completed.
- 31 Aug 2022 Planned End Date changed from 29 Aug 2022 to 10 Oct 2022.
- 08 Jul 2022 Planned End Date changed from 5 Apr 2023 to 29 Aug 2022.